FDA ACCEPTS FOR PRIORITY REVIEW BIOLOGICS LICENSE APPLICATION FOR REGN-EB3 TO TREAT EBOLA
TARRYTOWN, N.Y.,?April 16, 2020?/PRNewswire/ --
- REGN-EB3 developed via same rapid response platform currently being leveraged to develop novel COVID-19 antibody therapy
?View original content:http://www.prnewswire.com/news-releases/fda-accepts-for-priority-review-biologics-license-application-for-regn-eb3-to-treat-ebola-301041691.html
SOURCE?Regeneron Pharmaceuticals, Inc.